Guselkumab for Psoriasis
(TIG Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
Who Is on the Research Team?
Wilson Liao, MD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
Adults aged 18-70 with recent onset guttate psoriasis or long-standing plaque psoriasis, covering at least 5% of their body. Participants must be able to consent and follow the study plan. Women who can have children should use effective birth control. Excluded are those with certain infections like TB, HIV, hepatitis B/C, other skin diseases, severe illnesses, history of cancer (with some exceptions), or past psoriasis treatments including biologics.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks until week 44
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants who achieve PASI 50-75 continue treatment; those achieving PASI 75 or greater have therapy withdrawn and are re-treated upon relapse
What Are the Treatments Tested in This Trial?
Interventions
- Guselkumab
Guselkumab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
Janssen Biotech, Inc.
Industry Sponsor